OXiGENE, Inc. (Nasdaq :OXGN)  is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions. OXGN announced that the randomized Phase 2 study evaluating the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) to …Read More